Erin Glasgow, MD
Internal Medicine · Oklahoma City, OKNPI 1780621136
Payments from drug & device makers
Across 438 payments — averaging $14.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$1K
- Lilly USA, LLC$984
- Novo Nordisk$668
- AstraZeneca$658
- AbbVie$390
- Boehringer Ingelheim$342
- plus $2K from 24 others
What the payments were for
- Food & beverage$6,34697%
- Education$1763%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 120 | $1,472 |
| Lilly USA, LLC | 77 | $984 |
| Novo Nordisk | 53 | $668 |
| AstraZeneca(2 entities) | 30 | $658 |
| AbbVie(2 entities) | 20 | $390 |
| Boehringer Ingelheim | 19 | $342 |
| Astellas Pharma US Inc | 15 | $312 |
| Amgen(2 entities) | 14 | $257 |
| Abbott | 16 | $243 |
| Bayer | 13 | $234 |
| GSK | 11 | $169 |
| Amarin Pharma, Inc. | 11 | $164 |
| Sumitomo Pharma America, Inc. | 7 | $121 |
| Exact Sciences | 6 | $93 |
| Merck | 6 | $88 |
| Sanofi-aventis U.S. LLC | 4 | $65 |
| Novartis | 2 | $37 |
| Bristol Myers Squibb | 2 | $28 |
| Corcept Therapeutics | 1 | $26 |
| Gilead | 1 | $24 |
| Sobi, Inc | 1 | $23 |
| Actelion Pharmaceuticals US, Inc. | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Sunovion Pharmaceuticals Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Dexcom, Inc. | 1 | $14 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
| Antares Pharma, Inc. | 1 | $11 |
| Phathom Pharmaceuticals, Inc. | 1 | $8 |
| Bardy Diagnostics, Inc. | 1 | $6 |
How this compares
$6,522 in reported general payments places this provider in the 85th percentile of 840 internal medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 111 | $116,631 |
| OzempicSemaglutide | 98 | $109,486 |
| MyrbetriqMirabegron | 50 | $47,146 |
| TrulicityDulaglutide | 42 | $46,475 |
| EliquisApixaban | 40 | $44,951 |
| FarxigaDapagliflozin Propanediol | 24 | $39,300 |
| MounjaroTirzepatide | 23 | $33,816 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $24,608 |
| Breo ElliptaFluticasone/Vilanterol | 29 | $22,452 |
| Atorvastatin Calcium | 554 | $8,514 |
| Levothyroxine Sodium | 521 | $6,163 |
| Pravastatin Sodium | 178 | $4,776 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $4,663 |
| Montelukast Sodium | 251 | $4,655 |
| Omeprazole | 228 | $4,445 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $342 | $116,631111 claims |
| Novo NordiskOzempic | $668 | $109,48698 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $984 | $80,29165 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $169 | $51,43372 claims |
| Astellas Pharma US IncMyrbetriq | $312 | $47,14650 claims |
| PfizerEliquis | $1,472 | $44,95140 claims |
| AstraZenecaFarxiga | $658 | $39,30024 claims |
| AbbVieSynthroid | $390 | $3,44053 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 840 internal medicine providers in Oklahoma.
Other internal medicine in Oklahoma City
- Sagila GeorgeOklahoma City$1.8M
- Ryan MorganOklahoma City$775K
- Samid FarooquiOklahoma City$129K
- Minh PhanOklahoma City$77K
- Ali JafryOklahoma City$33K
- Stuart SchraderOklahoma City$29K
- Dale BratzlerOklahoma City$17K
- Karen ChopraOklahoma City$16K
- Charlsie RecordOklahoma City$14K
- Jeannette KelleyOklahoma City$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.